The domestic biotech industry has grown further to post revenues of Rs 10,273 crore ($2.56 billion) in fiscal 2007-08.
The biopharma industry in India is coming of age now and the next five years will be a very interesting period for the Indian biotechnology industry. While bioservices will continue to attract significant interest, and biogenerics exports to the regulated markets are likely to produce a quantum leap in company earnings, there is a growing club of companies in India that are developing novel biotechnology-based pharmaceutical products.
The top three — Serum, Biocon and Panacea — are in the biopharma space and retain their 2007 positions. They account for 25 per cent of the total revenue.
1 comment:
Biotech is more promising.
The domestic biotech industry has grown further to post revenues of Rs 10,273 crore ($2.56 billion) in fiscal 2007-08.
The biopharma industry in India is coming of age now and the next five years will be a very interesting period for the Indian biotechnology industry. While bioservices will continue to attract significant interest, and biogenerics exports to the regulated markets are likely to produce a quantum leap in company earnings, there is a growing club of companies in India that are developing novel biotechnology-based pharmaceutical products.
The top three — Serum, Biocon and Panacea — are in the biopharma space and retain their 2007 positions. They account for 25 per cent of the total revenue.
Post a Comment